BioSpace News Archive

MiNA eligible for up to 220 M€ in upfront, development and commercial milestone payments for first target.

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, announced that Snehal Patel, CEO of Greenwich LifeSciences, will participate in the following upcoming virtual investor conferences, highlighting the Company’s GP2 Phase IIb trial data and the planned Phase III trial.

Leading metabolomics based diagnostics company numares AG and analytical instrumentation and solution provider Bruker Corporation have signed an agreement to collaborate to bring new diagnostics tests utilizing NMR to the laboratory market for unmet medical needs.

Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company will host a virtual investor event titled Pegcetacoplan: Advancing the First Potential Treatment for Geographic Atrophy (GA) from 10:00 a.m. to noon ET on January 28, 2021.

Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on discovering, developing and delivering novel medicines for rare diseases, today announced that three oral presentations and ten posters highlighting its development programs for Lysosomal Disorders will be included at the 17th Annual WORLD Symposium ™ 2021 , to be held virtually February 8-12, 2021.

Molecular diagnostics company Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”), provides the following update to the market on further development on the COVID-19 serious disease risk Polygenic Risk Score Test (COVID-19 PRS Test) and expansion of the Company’s offering to include Germline Testing division.

- Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN.TA), today announced it will be featured as a presenting company at the Crohn’s & Colitis Congress® to be held from today January 21-24, 2021 .

4D pharma to Participate in 5 th Microbiome Movement Drug Development Summit Europe

OraSure Technologies, Inc., a leader in point-of-care diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services, announced that its Oragene®•Dx saliva collection device was included as a component in the De Novo authorization granted by the U.S. Food & Drug Administration to Helix for their Helix® Laboratory Platform1, a whole exome sequencing platform.

Based on a scientifically solid proof of concept in dogs and cats, an international IP portfolio, and a comprehensive scientific advisory board that includes key opinion leaders and experienced management, CureLab Veterinary intends to raise initial financing through a crowdfunding campaign set to launch within a month, and to become profitable within 36 months of raising funds.